Caracemide |
Catalog No.GC38896 |
Caracemide (NSC-253272) inhibits the enzyme ribonucleotide reductase of Escherichia coli.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 81424-67-1
Sample solution is provided at 25 µL, 10mM.
Caracemide (NSC-253272) inhibits the enzyme ribonucleotide reductase of Escherichia coli. Caracemide is a novel anticancer agent derived from a hydroxamic acid and has demonstrated to produce severe central nervous system (CNS) toxicity[1][2].
Caracemide inactivates R1 by covalent modification at the substrate-binding site and has a toxic metabolite, methylisocyanate (MIC), in vivo[1][2].
The mercapturic acid derivative AMCC was identified in urine rats following administration to rats of a single i.p. dose (6.6 mg/kg) of caracemide (NSC-253272)[1]. .
[1]. Slatter JG, et al. Studies on the metabolic fate of caracemide, an experimental antitumor agent, in the rat. Evidence for the release of methyl isocyanate in vivo. Chem Res Toxicol. 1993 May-Jun;6(3):335-40. [2]. Larsen IK, et al. Caracemide, a site-specific irreversible inhibitor of protein R1 of Escherichia coli ribonucleotide reductase. J Biol Chem. 1992 Jun 25;267(18):12627-31.
Average Rating: 5
(Based on Reviews and 1 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *